Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | ALB | P02768 | 3/20 | 1.00 |
| ▸ | GLI1 | P08151 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 1.00 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 1.00 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.82 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.82 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.82 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.82 |
| ▸ | CES2 | O00748 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betulinic Acid SCHEMBL14436762 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL3525115 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL13814590 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL4441993 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL10015159 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL13637571 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL23132693 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL9110960 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL22251646 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 | |
| Betulinic Acid SCHEMBL21264235 | 1.00 | RORC (1.00) | RORCPTPN1GPBAR1ALBGLI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| WO-2019153816-A1 | APPLICATION OF CHAENOMELES SPECIOSA BETULINIC ACID IN PREPARATION OF ANTI-HYPERTENSION MYOCARDIAL FIBROSIS MEDICINES | 南方医科大学 | 2019-08-15 | — | — | WO | disclosed |
| US-8642094-B2 | Synergistic pharmaceutical composition, method of making same and use of same | AFEXA LIFE SCIENCES INC. (CA) | 2014-02-04 | — | — | US | disclosed |
| US-20090285915-A1 | SYNERGISTIC PHARMACEUTICAL COMPOSITION, METHOD OF MAKING SAME AND USE OF SAME | AFEXA LIFE SCIENCES INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| WO-2009133458-A1 | PHARMACEUTICAL COMPOSITION COMPRISING EXTRACTS OF HUANGLIAN AND KU DING CHA EFFECTIVE FOR LOWERING BLOOD LIPID LEVELS | AFEXA LIFE SCIENCES INC. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20040097436-A1 | Triterpenes having antibacterial activity | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2004-05-20 | — | — | US | disclosed |
| US-6642217-B2 | Treating a fungal or yeast infection such as with betulin, allobetulin, and lupeol | NATURTEK, LLC | 2003-11-04 | — | — | US | disclosed |
| US-20020128210-A1 | Triterpenes having human antifungal and antiyeast activity | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128210-A1 | Triterpenes having human antifungal and antiyeast activity | ERG28, LSS, MANBA | RORC 682/4885PTPN1 4365/4885GPBAR1 2901/4885 |
| US-20040097436-A1 | Triterpenes having antibacterial activity | BET1, PGGT1B, LSS | RORC 173/4885PTPN1 3492/4885GPBAR1 819/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | RORC 1521/4885PTPN1 1588/4885GPBAR1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.